Theranica Achieves Landmark Coverage for Nerivio®
Nationwide Insurance Expansion Positions Neuromodulation Device as Mainstream Migraine Treatment
In a significant move, Theranica, a leader in neuromodulation therapeutics, has announced that its FDA-cleared Nerivio® device is now covered by health insurance for approximately 130 million lives across the nation. This development reflects a pivotal shift in how health payers view Remote Electrical Neuromodulation (REN) as a viable treatment option for migraine patients.
This coverage expansion largely stems from a comprehensive agreement with the Blue Cross Blue Shield Association and various independent BCBS member plans. Such widespread acceptance marks a momentous change, reinforcing that REN can be viewed as a mainstream treatment option akin to established migraine medications.
Nerivio operates by utilizing safe, non-invasive REN technology to manage both acute and preventive migraine symptoms for patients aged 8 and above. The recent year has witnessed an impressive number of health insurers recognizing Nerivio as a medically necessary treatment, enabling patients to access this innovative solution, previously reserved for more traditional medications.
Alon Ironi, CEO and Co-Founder of Theranica, expressed his enthusiasm, stating, "This milestone for coverage signifies a transformative moment for countless individuals afflicted with migraines, alongside a crucial turning point for our company. As REN becomes integrated into standard care pathways, it reflects healthcare systems' growing trust in evidence-based, drug-free methodologies that provide real value and long-term effectiveness."
Ironi further underscored the significance of this development, asserting that traditional migraine treatments involving needles and pills are becoming things of the past.
The decisions made by payers to cover this innovative therapy are backed by extensive clinical data and real-world experience, establishing REN as an essential part of a comprehensive migraine treatment approach.
Dr. William Young, a neurology expert at Jefferson Health, noted that such extensive coverage will change how clinical practices function. "When these therapies are reimbursements at a national level, practitioners can confidently include them in treatment strategies. This expanded insurance coverage enhances REN's position as a standard option and increases the variety of choices available to patients suffering from migraines."
Understanding Nerivio®
Nerivio® is a wearable device that provides both acute and preventive treatment for migraine sufferers without relying on medications or invasive procedures. Approved for use by patients as young as eight, Nerivio employs gentle electrical impulses to engage the body’s inherent pain regulation mechanisms, offering relief during migraine attacks while also diminishing the frequency of future episodes when used regularly. Powered by a user-friendly smartphone application, Nerivio ensures a straightforward and effective means for managing migraines without the dangers associated with systemic side effects.
About Theranica
Theranica is at the forefront of developing non-drug pain management solutions for various pain conditions. The company’s flagship product, Nerivio®, is the first and only prescribed REN device for both acute and preventive care in migraine patients. As an innovative solution utilized for over a million treatments across the country, Nerivio addresses the needs of diverse patient demographics, including children, veterans, and women of reproductive age. With a commitment to revolutionizing pain management devoid of pharmaceuticals, Theranica continuously strives to advance its neuromodulation technologies, enhancing the treatment paradigm for pain management.
Frequently Asked Questions
What is Nerivio®?
Nerivio® is a wearable device that uses remote electrical neuromodulation to provide drug-free treatment for migraines, suitable for both acute and preventive care.
How many lives does the Nerivio® coverage impact?
The current coverage for Nerivio® affects approximately 130 million lives across the United States.
Who can use Nerivio®?
Nerivio® is approved for use by patients aged 8 years and older, making it accessible for a wide range of individuals suffering from migraines.
What changes does this coverage signify for migraine treatment?
This new coverage signifies that Remote Electrical Neuromodulation is now recognized as a mainstream treatment option, comparable to traditional migraine medications.
Who is Theranica?
Theranica is a company focused on developing innovative, drug-free treatments for various pain conditions, with Nerivio® being their flagship product for migraine therapy.
